Register for our S/EIS Fund

Cancer is a leading cause of morbidity and mortality, accounting for nearly one third of all deaths, prompt investigation, diagnosis and treatment is more likely to ensure better outcomes for cancer patients.

In our Eighth o2h ChaiTime webinar we discussed how we can speed up translating basic cancer research into new cancer therapeutics to get drugs to the front-line more quickly.

The panelists
Chris Torrance CEO of PhoreMost

Chris is a Founder of Horizon Discovery (HZD:London) and CEO of fast growing PhoreMost in Cambridge UK, dedicated to first-in-class targets and focuses on drugging “Undruggable” targets.

Raj Chopra venture partner at ATP

Raj joined Apple Tree Partners ($2.5B under management) with an amazing career that spans positions spearheading cancer therapeutics, Celgene, AZ and the Institute of Cancer Research (San Diego, Boston, London).

Niall Martin CEO of Artios

Niall is a CEO of Artios ($84M Series B financing) to develop drugs for novel targets in the DNA Damage Repair pathway. Prior to Artios, Niall was co-founder of Mission Therapeutics.

Ruth Plummer Director of Sir Bobby Robson Cancer trials Research Centre

Ruth has a huge amount of experience at bringing oncology drugs through the clinic, she is the Director of the Sir Bobby Robson Cancer trials Research Centre with responsibility for early phase trials practice.

Ashok Venkitaraman Professor of Cancer Research (Moderator)

Ashok is the Ursula Zoellner Professor of Cancer Research, University of Cambridge & Emeritus Director, Medical Research Council Cancer Unit, Director-designate, Cancer Science Institute of Singapore, Director-designate, Cancer Programme.

Register for Invitations